Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Current Assets (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Current Assets for 6 consecutive years, with $2.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets fell 67.79% to $2.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.9 million, a 67.79% decrease, with the full-year FY2024 number at $5.3 million, up 133.51% from a year prior.
  • Current Assets was $2.9 million for Q3 2025 at Ensysce Biosciences, down from $5.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $15.7 million in Q4 2021 to a low of $228213.0 in Q1 2021.
  • A 5-year average of $6.0 million and a median of $5.3 million in 2022 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: skyrocketed 8662.1% in 2021, then plummeted 71.09% in 2023.
  • Ensysce Biosciences' Current Assets stood at $15.7 million in 2021, then crashed by 66.17% to $5.3 million in 2022, then tumbled by 56.81% to $2.3 million in 2023, then surged by 133.51% to $5.3 million in 2024, then plummeted by 45.21% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Current Assets are $2.9 million (Q3 2025), $5.3 million (Q2 2025), and $4.4 million (Q1 2025).